The Art of Negotiation Episode 11
페이지 정보
본문
Team Leader Yoon Joo-no is investigated by the audit team due to a whistleblower report related to the past investment in Jumbo Pharmaceutical. At the time, the investment contract was led by Executive Director Ha Tae-soo of the Strategy Planning Office, and Yoon Joo-no was his direct subordinate. The audit team catches on to the fact that Team Leader Yoon received the due diligence report from the Strategy Planning Office and applies full-scale pressure.
In the past, Ha Tae-soo receives a request from Dr. Ko of Jumbo Pharmaceutical to invest 8.7 billion won in new drug development. However, Ha Tae-soo demands a rebate, and Dr. Ko eventually offers 500 million won, but is rejected. Afterwards, Dr. Ko emphasizes to Yoon Joo-no that they are about to be selected as a national project and urges him to invest. However, Yoon Joo-no is suspicious of Dr. Ko's attitude of trying to induce a hasty investment without due diligence and refuses to invest.
The investment negotiations are ultimately concluded with the condition that Sanin will have the right to negotiate first and conduct due diligence, and Dr. Ko claims that 12.7 billion won is needed, inflating the required funds.
Meanwhile, the audit team recommends that Team Leader Yoon voluntarily resign, saying that there is sufficient evidence, and plans to convene a disciplinary committee. Executive Director Ha reports to Chairman Song his plan to file a lawsuit after firing Yoon Joo-no and receives approval. The disciplinary committee is formed with Ha Tae-soo as the chairman.
While reviewing the investigation into Jumbo Pharmaceutical, Yoon Joo-no uncovers a fraudulent act of importing and selling ADHD treatment drugs disguised as new drugs with only different packaging. The research lab was a warehouse with no real substance, and it is revealed that profits actually decreased while selling at a lower price than the import price. Oh Byun and Section Chief Kwak also confirm this fact, and their suspicions grow.
Team Leader Yoon calls Executive Director Ha to inform him of this, but realizes that Executive Director Ha is with Dr. Ko and realizes the complexity of the situation. Dr. Ko offers to hand over Jumbo Pharmaceutical stocks to Executive Director Ha and increase his profits tenfold through stock price manipulation.
In the past, Juno's older brother, Yoon Joo-seok, also swayed by Dr. Ko's suggestion, bought stocks and suffered losses, so he asked for help, but Juno emphasized that Jumbo Pharmaceutical was a fraud and warned that Sanin would not invest.
At the disciplinary committee, Yoon Joo-no eventually admitted to the information leak and also revealed that his brother owned 100 million won worth of Jumbo Pharmaceutical stocks. Executive Director Ha suggested that they end it with a dismissal, but Yoon Joo-no disagrees and declares that he will take responsibility to the end.
In the past, Ha Tae-soo receives a request from Dr. Ko of Jumbo Pharmaceutical to invest 8.7 billion won in new drug development. However, Ha Tae-soo demands a rebate, and Dr. Ko eventually offers 500 million won, but is rejected. Afterwards, Dr. Ko emphasizes to Yoon Joo-no that they are about to be selected as a national project and urges him to invest. However, Yoon Joo-no is suspicious of Dr. Ko's attitude of trying to induce a hasty investment without due diligence and refuses to invest.
The investment negotiations are ultimately concluded with the condition that Sanin will have the right to negotiate first and conduct due diligence, and Dr. Ko claims that 12.7 billion won is needed, inflating the required funds.
Meanwhile, the audit team recommends that Team Leader Yoon voluntarily resign, saying that there is sufficient evidence, and plans to convene a disciplinary committee. Executive Director Ha reports to Chairman Song his plan to file a lawsuit after firing Yoon Joo-no and receives approval. The disciplinary committee is formed with Ha Tae-soo as the chairman.
While reviewing the investigation into Jumbo Pharmaceutical, Yoon Joo-no uncovers a fraudulent act of importing and selling ADHD treatment drugs disguised as new drugs with only different packaging. The research lab was a warehouse with no real substance, and it is revealed that profits actually decreased while selling at a lower price than the import price. Oh Byun and Section Chief Kwak also confirm this fact, and their suspicions grow.
Team Leader Yoon calls Executive Director Ha to inform him of this, but realizes that Executive Director Ha is with Dr. Ko and realizes the complexity of the situation. Dr. Ko offers to hand over Jumbo Pharmaceutical stocks to Executive Director Ha and increase his profits tenfold through stock price manipulation.
In the past, Juno's older brother, Yoon Joo-seok, also swayed by Dr. Ko's suggestion, bought stocks and suffered losses, so he asked for help, but Juno emphasized that Jumbo Pharmaceutical was a fraud and warned that Sanin would not invest.
At the disciplinary committee, Yoon Joo-no eventually admitted to the information leak and also revealed that his brother owned 100 million won worth of Jumbo Pharmaceutical stocks. Executive Director Ha suggested that they end it with a dismissal, but Yoon Joo-no disagrees and declares that he will take responsibility to the end.
댓글목록
등록된 댓글이 없습니다.